Geneva/New Delhi–(ENEWSPF)–September 3, 2012 – German pharmaceutical company Bayer today heads to India’s Intellectual Property Appellate Board in Chennai in a bid to overturn a compulsory licence that has allowed more affordable generic versions of sorafenib tosylate, a cancer drug patented by Bayer, to be produced in the interests of public health. International humanitarian health organization Doctors Without Borders/Médecins Sans Frontières (MSF) has criticized Bayer for the move.
“Bayer’s appeal against this landmark ruling in…
